Sonnet BioTherapeutics Selects Abzena as Clinical Stage Manufacturing Partner for its IL-12-FHAB cytokine-derived Therapeutic Candidate

PRINCETON, N.J. & SAN DIEGO–(BUSINESS WIRE)–Sonnet BioTherapeutics selects Abzena as its manufacturing partner for SON-1010, an IL-12-FHAB cytokine, in preparation for clinical development.